Blis Technologies Limited — Regulatory Filings 2021

Apr 23, 2021

==> picture [157 x 58] intentionally omitted <==

23 April 2021

Probiotic strains approved in India

Blis Technologies Limited announces the Food Safety and Standards Authority of India (FSSAI) has granted approval of both BLIS M18™ and BLIS K12™ probiotic strains for use in health supplements.

Brian Watson, CEO of Blis Technologies, said “The COVID pandemic has caused delays in the normal approval timelines for this approval in India but we are delighted to have finally reached this milestone and look forward to continuing commercialisation plans with our agent for the India market.”

Blis Technologies have an existing relationship with RNA Nutrition who have supported this approval process and will act as our agent for the commercialisation of BLIS Ingredients™ in India. RNA Nutrition is an established selling agent for science based novel ingredients for human and animal health in India with a strong customer base.

Ends

For further information, please contact:

Brian Watson CEO +64 27 705 9133

About Blis Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Australia, Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz.

Website: www.unconditionalskin.com Instagram: @unconditionalskin #BLISQ24 #USC Facebook: @unconditionalskin

Blis Technologies Limited: 81 Glasgow Street, South Dunedin 9012, PO Box 2208, Dunedin 9012, New Zealand T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz